Could a Shingles Vaccine Lower the Dementia Risk? The Jury Is Still Out

What we currently know and when it might be worth having the vaccine.

Could a vaccine against a painful rash also protect our brains? Three questions matter: could it prevent dementia in healthy people, could it help those already experiencing memory problems, and is it worth having simply to avoid shingles?

Why might there be a dementia connection?

Scientists have two main theories for how the shingles vaccine might help lower the risk of dementia, both focused on reducing inflammation, which can stop cells from functioning and can damage healthy cells and tissues. First, the chickenpox virus hides inside nerve cells connected to the brain, so keeping it dormant stops flare-ups that can trigger brain inflammation and the build-up of amyloid protein linked to Alzheimer’s disease. Second, the vaccine may help reduce general, age-related inflammation throughout the body. Researchers are still studying these ideas.

The studies that started the excitement

The most persuasive early evidence came from Wales. In September 2013, people born on or after 2 September 1933 – aged 70 to just under 80 – qualified for a shingles vaccine, Zostavax (which is no longer used). Those born earlier did not. Comparing people born days apart, but assumed similar in every other way, created a powerful ‘natural experiment ’ that minimised bias. In 2025, a study analysed the records from 282,541 adults. Over seven years, the group eligible for a vaccine had 8.5% fewer new dementia diagnoses, with a stronger apparent effect in women. Because fewer than half those eligible actually received the jab, researchers estimated a 20% reduction in dementia among vaccine recipients. [1]

Just before the Welsh study publication, in 2024, Oxford researchers compared more than 200,000 adults aged 65-plus given either Zostavax or the newer Shingrix vaccine (now only used in the NHS). Over six years, the Shingrix group had 17% more time without a dementia diagnosis – equivalent to around 164 additional diagnosis-free days among those subsequently diagnosed. That is not the same as a 17% reduction in lifetime dementia risk. [2]

Then, in February 2026 a US study compared 65,800 Shingrix recipients aged 65-plus with 263,200 unvaccinated adults. The vaccinated group had 51% fewer dementia diagnoses. Note that vaccinated people typically have healthier lifestyles, better access to healthcare, and fewer underlying illnesses than unvaccinated people. For a fairer comparison, the vaccine effect was compared to adults who received a routine vaccine. With the obvious bias removed, the apparent advantage fell to 27%, which is still interesting, but less dramatic. [3]

So why are the reviews more cautious?

Correlation is not causation. People choosing vaccination may already exercise more, smoke less, be wealthier or have better access to healthcare. All can affect their dementia risk, and statistical adjustments cannot remove every difference. Whilst the Welsh birth-date comparison limited this bias, it is not the gold standard of a randomised double-blind trial.

An August 2026 meta-analysis combined findings from five independent data sources and found an association with approximately 28% lower dementia risk. However, the results varied markedly, so any real benefit could be smaller. [4]

A September 2026 reassessment by UCL looked again at the Welsh figures. It calculated a possible 18% reduction for people vaccinated, but the range of uncertainty included no benefit at all. [5]

The latest review, just published on 13 November 2026, examined 36 reports, including previous reviews. It found encouraging consistent associations between shingles vaccination and a lower risk of dementia but rated the overall evidence as ‘very low’ certainty and concluded that it did not support vaccination specifically for dementia prevention. However, it is also worth noting that none of these studies has established an increased dementia risk from vaccination. [6]

The established benefits – and possible extra ones

Shingles occurs when the chickenpox virus, which lies dormant in our nerves, reactivates. Its painful rash can be followed by long-lasting nerve pain and, occasionally, threatened eyesight. Unlike its use for dementia prevention, the benefit of vaccination here is established. Clinical trials found Shingrix about 97% effective against shingles in adults aged 50-plus and about 91% in those aged 70-plus. Substantial protection lasts at least 11 years and maybe longer. [7]

There may be wider benefits too. Even after adjusting for lifestyle and socioeconomic factors, a 2026 US study of 3,884 people over 70 still linked the shingles vaccine to lower inflammation and healthier markers of biological ageing. This too may add to the growing evidence around the benefits of reduced inflammation. [8]

Are there any downsides?

Yes, there are always downsides, although for most people the risks are very small. Shingrix needs two injections, and a sore arm, fatigue, headache, aches or fever are common for two or three days. Whilst serious allergic reactions are very rare, studies in adults aged 65-plus have identified a small increase in Guillain–Barré syndrome, a potentially serious nerve disorder, estimated at roughly three to seven additional cases per million doses. [7,9]

So who should consider vaccination – and when?

Timing matters because the risks of both shingles and dementia rise sharply with age. According to UK public health data, shingles cases climb from around 2 per 1,000 people each year in younger adults, to 4 in your 50s, 7 in their 60s, 8 in their 70s and over 11 in their 80s. Serious complications also become much more common as people age. The risk of developing long-term nerve pain after shingles climbs from around 10% in your 60s to 18% in your 70s, and over 25% in your 80s, alongside higher risks of vision loss and hospitalisation. [10]

Dementia diagnoses follow an even steeper curve with age. Data from the UK’s Cognitive Function and Ageing Study (CFAS II) shows new cases rising to around 4 per 1,000 in the late 60s, around 15 in the 70s, and over 40 in the late 80s. [14]

What does this mean?

In your 40s: Under UK licensing rules, Shingrix is only licensed for adults aged 50 and over, unless a younger adult has a severely weakened immune system who may qualify for free NHS vaccination. In this age group, for generally healthy people, both risks are extremely low. [7,9]

In your 50s: You can have a private vaccination. For example, at Boots the two-dose course costs £460. Whilst the risk of shingles is rising, for a generally healthy person, waiting until around 60 to reconsider may be reasonable – especially when the dementia benefit is still unproven. Paying now, however, buys earlier shingles protection. [10,11]

In your 60s and 70s: As shingles and its complications become more likely, vaccination looks increasingly attractive in its own right. In England, it is free on the NHS for people who turned 65 on or after 1 September 2023. For those in their early 60s, waiting a few years for NHS eligibility could save money. Note: From September 2028, the NHS is due to extend to people turning 60. [9,12]

And if you already have mild cognitive impairment?

Mild cognitive impairment (MCI) means noticeable changes in memory or thinking that do not necessarily amount to dementia. The research here is also encouraging, though still uncertain. In December 2025, researchers revisited the Welsh health records and found benefits across different stages. Among people already living with dementia, vaccinated patients were significantly less likely to die from the disease, suggesting it might help slow progression as well as prevent decline. However, this study examined the older Zostavax vaccine rather than Shingrix. [13]

Separately, a February 2026 US Shingrix study also reported lower rates of progression from new MCI to dementia among vaccinated adults. Even so, none of this proves that a vaccination treats MCI or stops existing memory problems from getting worse. [3,13]

The verdict

Just to be clear, this is a blog and not medical advice.

Having reviewed the evidence, the possibility that a shingles vaccination reduces the dementia risk merits ongoing research. Just to note, reducing inflammation may be a key part of staying healthy (and continues to be researched). Other routine adult vaccines, such as those for flu, pneumonia, and RSV, have also been linked to a lower risk of dementia. All of which appear to indicate that preventing infections helps protect the body and brain from harmful inflammation.

The vaccine Shingrix has a very low, but not zero, risk, and it significantly reduces the chance of shingles – a risk that rises with age and has increasing recovery complications with age

For a healthy adult in their 50s, waiting until 60 before considering private vaccination could make sense, but for now the vaccine would be private. For those 65 and older, eligible on the NHS, the case for protection against shingles appears strong.

Separately, the dementia evidence at best looks encouraging and at worst has not shown any established harm. This could therefore be a small positive nudge, rather than the single deciding factor. Of course, some may consider even a small and unproven dementia risk reduction sufficient to justify the vaccine.

The right age and choice would depend on your health and priorities and should be discussed with your GP or a qualified medical practitioner.

Whilst the jury on dementia remains out, on shingles, the evidence is compelling.

Sources and further reading

[1] Nature (2025): Welsh birth-date natural experiment

[2] Nature Medicine (2024): Shingrix versus Zostavax

[3] Nature Communications (February 2026): Shingrix, dementia and MCI

[4] Vaccines (August 2026): five-source meta-analysis

[5] Brain, Behavior, and Immunity (September 2026): UCL reassessment

[6] Vaccines (13 November 2026): review of 36 reports

[7] Shingrix UK product information: efficacy, duration and safety

[8] Journals of Gerontology (2026): inflammation and biological ageing

[9] NHS: shingles vaccination eligibility and side effects

[10] BMJ Open (2018): shingles incidence by age in England

[11] Boots: private shingles vaccination price

[12] UKHSA: shingles vaccination programme guidance

[13] Cell (December 2025): vaccine and stages of cognitive decline

[14] Nature Communications (2016): CFAS II dementia incidence by age

Take Control of Your Biological Age

Download a.genius today and start your personalised journey towards a longer, healthier future.